Scientific interest in the therapeutic potential of psychedelics has been experiencing significant growth. Understanding the perceptions of psychedelic assisted psychotherapy (PAP) among health professional, patients, and the public is essential to guide future research objectives, trial protocols, and identify any barriers to future implementation.A comprehensive search of the databases (Medline, EMBASE, PSYCHinfo, SCOPUS, and Web of Science) was conducted on the 29th of November, 2022. This review included cross-sectional, longitudinal, and quasi-experimental studies published in peer-reviewed journals exploring perceptions of PAP among the three stakeholder groups. Studies were limited to English-language and the years 2012–2022. The protocol and review was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.The sample consisted of 29 studies, including n = 17 health professional, n = 6 patients, and n = 6 public. Broadly, knowledge of PAP was low among all three stakeholder groups. There was mixed to positive belief in the therapeutic potential of psychedelics, with male gender, younger age, and personal psychedelic experience/knowledge being key predictors of more favourable views. The majority of findings reported strong endorsement of further research. Consistent themes were identified surrounding concerns about legal status, funding, access, side-effects, and implementation.The evaluated research indicates a need for further research that will provide clarity about safety and elucidate how PAP may be implemented in public health settings. Further education of health professionals and the public should be a priority.
科学界对迷幻药治疗潜力的兴趣一直在大幅增长。2022 年 11 月 29 日，我们对数据库（Medline、EMBASE、PSYCHinfo、SCOPUS 和 Web of Science）进行了全面检索。本综述包括在同行评审期刊上发表的横向、纵向和准实验性研究，这些研究探讨了三个利益相关群体对 PAP 的看法。研究仅限于英语和 2012-2022 年。样本由 29 项研究组成，包括 n = 17 名卫生专业人员、n = 6 名患者和 n = 6 名公众。总体而言，所有三个利益相关群体对 PAP 的了解程度都很低。对于迷幻药的治疗潜力，人们的看法有好有坏，男性、年轻和个人迷幻药经历/知识是预测更赞成其观点的主要因素。大多数研究结果都强烈支持进一步的研究。所评估的研究表明，有必要开展进一步的研究，以澄清安全性问题，并阐明如何在公共卫生环境中实施 PAP。对卫生专业人员和公众的进一步教育应成为优先事项。
{"title":"Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: A systematic review","authors":"Alesha Wells, Merciana Fernandes, Lisa Reynolds","doi":"10.1556/2054.2023.00294","DOIUrl":"https://doi.org/10.1556/2054.2023.00294","url":null,"abstract":"Scientific interest in the therapeutic potential of psychedelics has been experiencing significant growth. Understanding the perceptions of psychedelic assisted psychotherapy (PAP) among health professional, patients, and the public is essential to guide future research objectives, trial protocols, and identify any barriers to future implementation.A comprehensive search of the databases (Medline, EMBASE, PSYCHinfo, SCOPUS, and Web of Science) was conducted on the 29th of November, 2022. This review included cross-sectional, longitudinal, and quasi-experimental studies published in peer-reviewed journals exploring perceptions of PAP among the three stakeholder groups. Studies were limited to English-language and the years 2012–2022. The protocol and review was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.The sample consisted of 29 studies, including n = 17 health professional, n = 6 patients, and n = 6 public. Broadly, knowledge of PAP was low among all three stakeholder groups. There was mixed to positive belief in the therapeutic potential of psychedelics, with male gender, younger age, and personal psychedelic experience/knowledge being key predictors of more favourable views. The majority of findings reported strong endorsement of further research. Consistent themes were identified surrounding concerns about legal status, funding, access, side-effects, and implementation.The evaluated research indicates a need for further research that will provide clarity about safety and elucidate how PAP may be implemented in public health settings. Further education of health professionals and the public should be a priority.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139863127","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ann M. Inouye, Aaron S. Wolfgang, Lianne T. Philhower
In 2021, the final series of phase 3 clinical trials looking at MDMA-AT for treatment-resistant post-traumatic stress disorder (PTSD) found that 71.2% of 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants no longer met criteria for PTSD. MDMA-assisted therapy is not US Food and Drug Administration (FDA) approved in treating borderline personality disorder (BPD), and while PTSD is quite different from BPD, it is possible that some of the beneficial effects of MDMA-assisted therapy may be applicable in treating BPD. Interviewing two clinicians utilizing dialectical behavioral therapy treatment and two MDMA-assisted therapy clinicians was one way to examine the phenomenology of MDMA-assisted therapy with BPD individuals in a thoughtful manner. An exploratory, qualitative, interview-based study assessed clinicians' perspectives of MDMA-assisted therapy and BPD and increased our understanding of underlying therapeutic mechanisms and processes and the role of pharmacological factors in these treatment modalities, optimizing treatment context, and leading to improved clinical responses and patient recovery. The codes generated unique perspectives of the participants revealing a chronological narrative which included three phases of treatment.
{"title":"MDMA-assisted dialectical behavioral therapy for borderline personality disorder: A qualitative study of mental health clinicians","authors":"Ann M. Inouye, Aaron S. Wolfgang, Lianne T. Philhower","doi":"10.1556/2054.2023.00281","DOIUrl":"https://doi.org/10.1556/2054.2023.00281","url":null,"abstract":"In 2021, the final series of phase 3 clinical trials looking at MDMA-AT for treatment-resistant post-traumatic stress disorder (PTSD) found that 71.2% of 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants no longer met criteria for PTSD. MDMA-assisted therapy is not US Food and Drug Administration (FDA) approved in treating borderline personality disorder (BPD), and while PTSD is quite different from BPD, it is possible that some of the beneficial effects of MDMA-assisted therapy may be applicable in treating BPD. Interviewing two clinicians utilizing dialectical behavioral therapy treatment and two MDMA-assisted therapy clinicians was one way to examine the phenomenology of MDMA-assisted therapy with BPD individuals in a thoughtful manner. An exploratory, qualitative, interview-based study assessed clinicians' perspectives of MDMA-assisted therapy and BPD and increased our understanding of underlying therapeutic mechanisms and processes and the role of pharmacological factors in these treatment modalities, optimizing treatment context, and leading to improved clinical responses and patient recovery. The codes generated unique perspectives of the participants revealing a chronological narrative which included three phases of treatment.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139804852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Scientific interest in the therapeutic potential of psychedelics has been experiencing significant growth. Understanding the perceptions of psychedelic assisted psychotherapy (PAP) among health professional, patients, and the public is essential to guide future research objectives, trial protocols, and identify any barriers to future implementation.A comprehensive search of the databases (Medline, EMBASE, PSYCHinfo, SCOPUS, and Web of Science) was conducted on the 29th of November, 2022. This review included cross-sectional, longitudinal, and quasi-experimental studies published in peer-reviewed journals exploring perceptions of PAP among the three stakeholder groups. Studies were limited to English-language and the years 2012–2022. The protocol and review was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.The sample consisted of 29 studies, including n = 17 health professional, n = 6 patients, and n = 6 public. Broadly, knowledge of PAP was low among all three stakeholder groups. There was mixed to positive belief in the therapeutic potential of psychedelics, with male gender, younger age, and personal psychedelic experience/knowledge being key predictors of more favourable views. The majority of findings reported strong endorsement of further research. Consistent themes were identified surrounding concerns about legal status, funding, access, side-effects, and implementation.The evaluated research indicates a need for further research that will provide clarity about safety and elucidate how PAP may be implemented in public health settings. Further education of health professionals and the public should be a priority.
科学界对迷幻药治疗潜力的兴趣一直在大幅增长。2022 年 11 月 29 日，我们对数据库（Medline、EMBASE、PSYCHinfo、SCOPUS 和 Web of Science）进行了全面检索。本综述包括在同行评审期刊上发表的横向、纵向和准实验性研究，这些研究探讨了三个利益相关群体对 PAP 的看法。研究仅限于英语和 2012-2022 年。样本由 29 项研究组成，包括 n = 17 名卫生专业人员、n = 6 名患者和 n = 6 名公众。总体而言，所有三个利益相关群体对 PAP 的了解程度都很低。对于迷幻药的治疗潜力，人们的看法有好有坏，男性、年轻和个人迷幻药经历/知识是预测更赞成其观点的主要因素。大多数研究结果都强烈支持进一步的研究。所评估的研究表明，有必要开展进一步的研究，以澄清安全性问题，并阐明如何在公共卫生环境中实施 PAP。对卫生专业人员和公众的进一步教育应成为优先事项。
{"title":"Perceptions and attitudes towards psychedelic-assisted psychotherapy among health professionals, patients, and the public: A systematic review","authors":"Alesha Wells, Merciana Fernandes, Lisa Reynolds","doi":"10.1556/2054.2023.00294","DOIUrl":"https://doi.org/10.1556/2054.2023.00294","url":null,"abstract":"Scientific interest in the therapeutic potential of psychedelics has been experiencing significant growth. Understanding the perceptions of psychedelic assisted psychotherapy (PAP) among health professional, patients, and the public is essential to guide future research objectives, trial protocols, and identify any barriers to future implementation.A comprehensive search of the databases (Medline, EMBASE, PSYCHinfo, SCOPUS, and Web of Science) was conducted on the 29th of November, 2022. This review included cross-sectional, longitudinal, and quasi-experimental studies published in peer-reviewed journals exploring perceptions of PAP among the three stakeholder groups. Studies were limited to English-language and the years 2012–2022. The protocol and review was conducted according to the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines.The sample consisted of 29 studies, including n = 17 health professional, n = 6 patients, and n = 6 public. Broadly, knowledge of PAP was low among all three stakeholder groups. There was mixed to positive belief in the therapeutic potential of psychedelics, with male gender, younger age, and personal psychedelic experience/knowledge being key predictors of more favourable views. The majority of findings reported strong endorsement of further research. Consistent themes were identified surrounding concerns about legal status, funding, access, side-effects, and implementation.The evaluated research indicates a need for further research that will provide clarity about safety and elucidate how PAP may be implemented in public health settings. Further education of health professionals and the public should be a priority.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139803273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ann M. Inouye, Aaron S. Wolfgang, Lianne T. Philhower
In 2021, the final series of phase 3 clinical trials looking at MDMA-AT for treatment-resistant post-traumatic stress disorder (PTSD) found that 71.2% of 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants no longer met criteria for PTSD. MDMA-assisted therapy is not US Food and Drug Administration (FDA) approved in treating borderline personality disorder (BPD), and while PTSD is quite different from BPD, it is possible that some of the beneficial effects of MDMA-assisted therapy may be applicable in treating BPD. Interviewing two clinicians utilizing dialectical behavioral therapy treatment and two MDMA-assisted therapy clinicians was one way to examine the phenomenology of MDMA-assisted therapy with BPD individuals in a thoughtful manner. An exploratory, qualitative, interview-based study assessed clinicians' perspectives of MDMA-assisted therapy and BPD and increased our understanding of underlying therapeutic mechanisms and processes and the role of pharmacological factors in these treatment modalities, optimizing treatment context, and leading to improved clinical responses and patient recovery. The codes generated unique perspectives of the participants revealing a chronological narrative which included three phases of treatment.
{"title":"MDMA-assisted dialectical behavioral therapy for borderline personality disorder: A qualitative study of mental health clinicians","authors":"Ann M. Inouye, Aaron S. Wolfgang, Lianne T. Philhower","doi":"10.1556/2054.2023.00281","DOIUrl":"https://doi.org/10.1556/2054.2023.00281","url":null,"abstract":"In 2021, the final series of phase 3 clinical trials looking at MDMA-AT for treatment-resistant post-traumatic stress disorder (PTSD) found that 71.2% of 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants no longer met criteria for PTSD. MDMA-assisted therapy is not US Food and Drug Administration (FDA) approved in treating borderline personality disorder (BPD), and while PTSD is quite different from BPD, it is possible that some of the beneficial effects of MDMA-assisted therapy may be applicable in treating BPD. Interviewing two clinicians utilizing dialectical behavioral therapy treatment and two MDMA-assisted therapy clinicians was one way to examine the phenomenology of MDMA-assisted therapy with BPD individuals in a thoughtful manner. An exploratory, qualitative, interview-based study assessed clinicians' perspectives of MDMA-assisted therapy and BPD and increased our understanding of underlying therapeutic mechanisms and processes and the role of pharmacological factors in these treatment modalities, optimizing treatment context, and leading to improved clinical responses and patient recovery. The codes generated unique perspectives of the participants revealing a chronological narrative which included three phases of treatment.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139864715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The present research study investigated the phenomenon of recreational use of psychedelics at music festivals, analysing whether the resulting experiences could possibly be recognized as valuable in terms of preventive mental health strategies. Quantitative (online survey) and qualitative (interviews) research methods have been combined to illuminate 3 main topics: motivation for the setting choice; the nature of the resulting experiences & their influence on people's lives; learnings from psychedelic experiences at music festivals (PEMF).Among other findings, motivation evolved around fun, enhancing the sensory exploration of the world, and deepening the connection to its diverse parts through engagement with art, nature and other beings. Factors, distinguishing music festivals from other settings, were significant for the setting choice (non-controllability of the environment, community & connection aspect, diversity & richness of the surroundings, pharmacological specifics). Remarkably, the non-controllability of the environment, otherwise avoided in the psychedelic research, contributed to the life-changing effects of PEMF. Exploration of their nature showed that, mostly rooted in poly-drug use, the enjoyable were clearly dominating over the challenging ones. The mystical PEMF appeared to be surprisingly common. Participants shared the related life-changing effects, centred around changed perception (increased empathy, awareness, acceptance; new perspectives, etc.) and changed behaviours (increased mindfulness in all life areas; making different life choices; changed approach to relationships, etc.). Except for post MDMA recovery, a positive impact of PEMF on mental health and the emotional state of the participants was reported, referring to increased levels of happiness, compassion, awe, trust and to emotional balance. This study showed the potential value of PEMF in terms of preventive mental health strategies in various forms. Acknowledging these findings as well as the existence of potential risks for triggering psychiatric conditions, de-stigmatization of recreational use could help introduce meaningful changes, including substance testing availability, prioritization of education as well as mandatory welfare and harm reduction services on-site.
{"title":"Recreational use of psychedelics at music festivals: Motivation, nature of experiences and learnings","authors":"Iryana Mosina, Pascal Michael","doi":"10.1556/2054.2023.00282","DOIUrl":"https://doi.org/10.1556/2054.2023.00282","url":null,"abstract":"The present research study investigated the phenomenon of recreational use of psychedelics at music festivals, analysing whether the resulting experiences could possibly be recognized as valuable in terms of preventive mental health strategies. Quantitative (online survey) and qualitative (interviews) research methods have been combined to illuminate 3 main topics: motivation for the setting choice; the nature of the resulting experiences & their influence on people's lives; learnings from psychedelic experiences at music festivals (PEMF).Among other findings, motivation evolved around fun, enhancing the sensory exploration of the world, and deepening the connection to its diverse parts through engagement with art, nature and other beings. Factors, distinguishing music festivals from other settings, were significant for the setting choice (non-controllability of the environment, community & connection aspect, diversity & richness of the surroundings, pharmacological specifics). Remarkably, the non-controllability of the environment, otherwise avoided in the psychedelic research, contributed to the life-changing effects of PEMF. Exploration of their nature showed that, mostly rooted in poly-drug use, the enjoyable were clearly dominating over the challenging ones. The mystical PEMF appeared to be surprisingly common. Participants shared the related life-changing effects, centred around changed perception (increased empathy, awareness, acceptance; new perspectives, etc.) and changed behaviours (increased mindfulness in all life areas; making different life choices; changed approach to relationships, etc.). Except for post MDMA recovery, a positive impact of PEMF on mental health and the emotional state of the participants was reported, referring to increased levels of happiness, compassion, awe, trust and to emotional balance. This study showed the potential value of PEMF in terms of preventive mental health strategies in various forms. Acknowledging these findings as well as the existence of potential risks for triggering psychiatric conditions, de-stigmatization of recreational use could help introduce meaningful changes, including substance testing availability, prioritization of education as well as mandatory welfare and harm reduction services on-site.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139869638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
The present research study investigated the phenomenon of recreational use of psychedelics at music festivals, analysing whether the resulting experiences could possibly be recognized as valuable in terms of preventive mental health strategies. Quantitative (online survey) and qualitative (interviews) research methods have been combined to illuminate 3 main topics: motivation for the setting choice; the nature of the resulting experiences & their influence on people's lives; learnings from psychedelic experiences at music festivals (PEMF).Among other findings, motivation evolved around fun, enhancing the sensory exploration of the world, and deepening the connection to its diverse parts through engagement with art, nature and other beings. Factors, distinguishing music festivals from other settings, were significant for the setting choice (non-controllability of the environment, community & connection aspect, diversity & richness of the surroundings, pharmacological specifics). Remarkably, the non-controllability of the environment, otherwise avoided in the psychedelic research, contributed to the life-changing effects of PEMF. Exploration of their nature showed that, mostly rooted in poly-drug use, the enjoyable were clearly dominating over the challenging ones. The mystical PEMF appeared to be surprisingly common. Participants shared the related life-changing effects, centred around changed perception (increased empathy, awareness, acceptance; new perspectives, etc.) and changed behaviours (increased mindfulness in all life areas; making different life choices; changed approach to relationships, etc.). Except for post MDMA recovery, a positive impact of PEMF on mental health and the emotional state of the participants was reported, referring to increased levels of happiness, compassion, awe, trust and to emotional balance. This study showed the potential value of PEMF in terms of preventive mental health strategies in various forms. Acknowledging these findings as well as the existence of potential risks for triggering psychiatric conditions, de-stigmatization of recreational use could help introduce meaningful changes, including substance testing availability, prioritization of education as well as mandatory welfare and harm reduction services on-site.
{"title":"Recreational use of psychedelics at music festivals: Motivation, nature of experiences and learnings","authors":"Iryana Mosina, Pascal Michael","doi":"10.1556/2054.2023.00282","DOIUrl":"https://doi.org/10.1556/2054.2023.00282","url":null,"abstract":"The present research study investigated the phenomenon of recreational use of psychedelics at music festivals, analysing whether the resulting experiences could possibly be recognized as valuable in terms of preventive mental health strategies. Quantitative (online survey) and qualitative (interviews) research methods have been combined to illuminate 3 main topics: motivation for the setting choice; the nature of the resulting experiences & their influence on people's lives; learnings from psychedelic experiences at music festivals (PEMF).Among other findings, motivation evolved around fun, enhancing the sensory exploration of the world, and deepening the connection to its diverse parts through engagement with art, nature and other beings. Factors, distinguishing music festivals from other settings, were significant for the setting choice (non-controllability of the environment, community & connection aspect, diversity & richness of the surroundings, pharmacological specifics). Remarkably, the non-controllability of the environment, otherwise avoided in the psychedelic research, contributed to the life-changing effects of PEMF. Exploration of their nature showed that, mostly rooted in poly-drug use, the enjoyable were clearly dominating over the challenging ones. The mystical PEMF appeared to be surprisingly common. Participants shared the related life-changing effects, centred around changed perception (increased empathy, awareness, acceptance; new perspectives, etc.) and changed behaviours (increased mindfulness in all life areas; making different life choices; changed approach to relationships, etc.). Except for post MDMA recovery, a positive impact of PEMF on mental health and the emotional state of the participants was reported, referring to increased levels of happiness, compassion, awe, trust and to emotional balance. This study showed the potential value of PEMF in terms of preventive mental health strategies in various forms. Acknowledging these findings as well as the existence of potential risks for triggering psychiatric conditions, de-stigmatization of recreational use could help introduce meaningful changes, including substance testing availability, prioritization of education as well as mandatory welfare and harm reduction services on-site.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139809752","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jeremy Weleff, A. Anand, Elizabeth N. Dewey, Brian S. Barnett
Lysergic acid diethylamide (LSD) use has risen in the United States in recent years amid increased interest in therapeutic applications of psychedelics. Despite this, contemporary epidemiological investigations of LSD users are few. To expand the literature on this topic, we sought to characterize past-year LSD users in the United States and investigate recent demographic evolution within this population.Using National Survey on Drug Use and Health (NSDUH) data from 2015–2019, we investigated correlates of past-year LSD use and associated changes over the study period.Past-year LSD use increased by 47% from 2015 to 2019 (0.59%–0.87%). However, among people reporting past-year hallucinogen use disorder there was no significant proportional increase in LSD users. Notable correlates of LSD use on multivariable analysis were: increased LSD access, lower perceived risk of trying LSD, low income, fewer children in the home, being approached by someone selling drugs in the past month, and past-year suicide attempt among people age 18 and older. We found no associations with unemployment, arrest history, or past-year psychological distress. From 2015 to 2019, the proportion of respondents reporting past-year LSD use who were age 26–34 and married increased. Past-year LSD use among lifetime users of methamphetamine also rose.Though still uncommonly used in the United States, LSD's societal acceptance may be increasing. Overall, LSD does not appear to contribute significantly to the country's public health problems.
{"title":"LSD use in the United States: Examining user demographics and their evolution from 2015–2019","authors":"Jeremy Weleff, A. Anand, Elizabeth N. Dewey, Brian S. Barnett","doi":"10.1556/2054.2024.00309","DOIUrl":"https://doi.org/10.1556/2054.2024.00309","url":null,"abstract":"Lysergic acid diethylamide (LSD) use has risen in the United States in recent years amid increased interest in therapeutic applications of psychedelics. Despite this, contemporary epidemiological investigations of LSD users are few. To expand the literature on this topic, we sought to characterize past-year LSD users in the United States and investigate recent demographic evolution within this population.Using National Survey on Drug Use and Health (NSDUH) data from 2015–2019, we investigated correlates of past-year LSD use and associated changes over the study period.Past-year LSD use increased by 47% from 2015 to 2019 (0.59%–0.87%). However, among people reporting past-year hallucinogen use disorder there was no significant proportional increase in LSD users. Notable correlates of LSD use on multivariable analysis were: increased LSD access, lower perceived risk of trying LSD, low income, fewer children in the home, being approached by someone selling drugs in the past month, and past-year suicide attempt among people age 18 and older. We found no associations with unemployment, arrest history, or past-year psychological distress. From 2015 to 2019, the proportion of respondents reporting past-year LSD use who were age 26–34 and married increased. Past-year LSD use among lifetime users of methamphetamine also rose.Though still uncommonly used in the United States, LSD's societal acceptance may be increasing. Overall, LSD does not appear to contribute significantly to the country's public health problems.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139889839","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jeremy Weleff, A. Anand, Elizabeth N. Dewey, Brian S. Barnett
Lysergic acid diethylamide (LSD) use has risen in the United States in recent years amid increased interest in therapeutic applications of psychedelics. Despite this, contemporary epidemiological investigations of LSD users are few. To expand the literature on this topic, we sought to characterize past-year LSD users in the United States and investigate recent demographic evolution within this population.Using National Survey on Drug Use and Health (NSDUH) data from 2015–2019, we investigated correlates of past-year LSD use and associated changes over the study period.Past-year LSD use increased by 47% from 2015 to 2019 (0.59%–0.87%). However, among people reporting past-year hallucinogen use disorder there was no significant proportional increase in LSD users. Notable correlates of LSD use on multivariable analysis were: increased LSD access, lower perceived risk of trying LSD, low income, fewer children in the home, being approached by someone selling drugs in the past month, and past-year suicide attempt among people age 18 and older. We found no associations with unemployment, arrest history, or past-year psychological distress. From 2015 to 2019, the proportion of respondents reporting past-year LSD use who were age 26–34 and married increased. Past-year LSD use among lifetime users of methamphetamine also rose.Though still uncommonly used in the United States, LSD's societal acceptance may be increasing. Overall, LSD does not appear to contribute significantly to the country's public health problems.
{"title":"LSD use in the United States: Examining user demographics and their evolution from 2015–2019","authors":"Jeremy Weleff, A. Anand, Elizabeth N. Dewey, Brian S. Barnett","doi":"10.1556/2054.2024.00309","DOIUrl":"https://doi.org/10.1556/2054.2024.00309","url":null,"abstract":"Lysergic acid diethylamide (LSD) use has risen in the United States in recent years amid increased interest in therapeutic applications of psychedelics. Despite this, contemporary epidemiological investigations of LSD users are few. To expand the literature on this topic, we sought to characterize past-year LSD users in the United States and investigate recent demographic evolution within this population.Using National Survey on Drug Use and Health (NSDUH) data from 2015–2019, we investigated correlates of past-year LSD use and associated changes over the study period.Past-year LSD use increased by 47% from 2015 to 2019 (0.59%–0.87%). However, among people reporting past-year hallucinogen use disorder there was no significant proportional increase in LSD users. Notable correlates of LSD use on multivariable analysis were: increased LSD access, lower perceived risk of trying LSD, low income, fewer children in the home, being approached by someone selling drugs in the past month, and past-year suicide attempt among people age 18 and older. We found no associations with unemployment, arrest history, or past-year psychological distress. From 2015 to 2019, the proportion of respondents reporting past-year LSD use who were age 26–34 and married increased. Past-year LSD use among lifetime users of methamphetamine also rose.Though still uncommonly used in the United States, LSD's societal acceptance may be increasing. Overall, LSD does not appear to contribute significantly to the country's public health problems.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139829825","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Neşe Devenot, Brian A. Pace, Jason Slot, Alan K. Davis
{"title":"Psychedemia: Charting the future of interdisciplinary Psychedelic Studies","authors":"Neşe Devenot, Brian A. Pace, Jason Slot, Alan K. Davis","doi":"10.1556/2054.2023.00358","DOIUrl":"https://doi.org/10.1556/2054.2023.00358","url":null,"abstract":"","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139146297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ann M. Inouye, Aaron S. Wolfgang, Lianne T. Philhower
Associated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and stigmatized conditions. Individuals with BPD are frequently labeled as treatment-resistant patients. Furthermore, 25–58% of BPD individuals have a comorbid diagnosis of post-traumatic stress disorder (PTSD), and BPD may be conceptualized as a trauma-spectrum disorder. In Phase 3 clinical trials for 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants for treatment-resistant PTSD found that up to 71.2% no longer met the criteria for PTSD. While PTSD is quite different from BPD, a qualitative exploration on the overlap in etiology and conceptualization provided new perspectives by interviewing two clinicians who focus their treatment with BPD diagnosed individuals and two MDMA-assisted therapy clinicians. This research examines the etiological, conceptualization, and therapeutic mechanisms of MDMA-assisted therapists and dialectical behavioral therapists. Through eight qualitative interviews, perspectives of the four participants revealed the similarities and limitations of both treatments.
{"title":"MDMA-assisted therapy for borderline personality disorder","authors":"Ann M. Inouye, Aaron S. Wolfgang, Lianne T. Philhower","doi":"10.1556/2054.2023.00196","DOIUrl":"https://doi.org/10.1556/2054.2023.00196","url":null,"abstract":"Associated with high-risk behavior, borderline personality disorder (BPD) remains one of the field's most misunderstood, misdiagnosed, and stigmatized conditions. Individuals with BPD are frequently labeled as treatment-resistant patients. Furthermore, 25–58% of BPD individuals have a comorbid diagnosis of post-traumatic stress disorder (PTSD), and BPD may be conceptualized as a trauma-spectrum disorder. In Phase 3 clinical trials for 3,4-methylenedioxymethamphetamine (MDMA) full-dose participants for treatment-resistant PTSD found that up to 71.2% no longer met the criteria for PTSD. While PTSD is quite different from BPD, a qualitative exploration on the overlap in etiology and conceptualization provided new perspectives by interviewing two clinicians who focus their treatment with BPD diagnosed individuals and two MDMA-assisted therapy clinicians. This research examines the etiological, conceptualization, and therapeutic mechanisms of MDMA-assisted therapists and dialectical behavioral therapists. Through eight qualitative interviews, perspectives of the four participants revealed the similarities and limitations of both treatments.","PeriodicalId":34732,"journal":{"name":"Journal of Psychedelic Studies","volume":null,"pages":null},"PeriodicalIF":4.5,"publicationDate":"2023-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138971058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：